ValuEngine downgraded shares of Pluristem Therapeutics (NASDAQ:PSTI) from a sell rating to a strong sell rating in a research report released on Wednesday, December 20th.
PSTI has been the topic of a number of other reports. HC Wainwright reaffirmed a buy rating and issued a $3.50 price objective on shares of Pluristem Therapeutics in a report on Thursday, November 9th. Maxim Group set a $3.00 target price on Pluristem Therapeutics and gave the stock a buy rating in a report on Thursday, October 26th. Zacks Investment Research raised Pluristem Therapeutics from a sell rating to a hold rating in a report on Wednesday, November 22nd. Finally, Seaport Global Securities reissued a buy rating and set a $5.00 target price on shares of Pluristem Therapeutics in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $3.83.
Shares of Pluristem Therapeutics (PSTI) traded up $0.09 during trading on Wednesday, hitting $1.61. The stock had a trading volume of 933,600 shares, compared to its average volume of 301,501. Pluristem Therapeutics has a one year low of $1.04 and a one year high of $2.12. The company has a market cap of $175.14, a PE ratio of -5.03 and a beta of 0.09.
A number of large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC boosted its stake in Pluristem Therapeutics by 15.0% in the third quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock valued at $402,000 after buying an additional 34,742 shares in the last quarter. Psagot Investment House Ltd. raised its position in shares of Pluristem Therapeutics by 1,705.2% during the third quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock worth $196,000 after acquiring an additional 122,347 shares during the last quarter. Finally, Heritage Investors Management Corp bought a new position in shares of Pluristem Therapeutics during the third quarter worth about $113,000. 4.31% of the stock is currently owned by institutional investors and hedge funds.
About Pluristem Therapeutics
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.